APA (7th ed.) Citation

Robak, T., Jin, J., Pylypenko, H., Verhoef, G., Siritanaratkul, N., Drach, J., . . . investigators, L. (2018). Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: Final overall survival results of a randomised, open-label, phase 3 study. Lancet Oncology, 19(11), 1449. https://doi.org/10.1016/S1470-2045(18)30685-5

Chicago Style (17th ed.) Citation

Robak, Tadeusz, et al. "Frontline Bortezomib, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (VR-CAP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Transplantation-ineligible Patients with Newly Diagnosed Mantle Cell Lymphoma: Final Overall Survival Results of a Randomised, Open-label, Phase 3 Study." Lancet Oncology 19, no. 11 (2018): 1449. https://doi.org/10.1016/S1470-2045(18)30685-5.

MLA (9th ed.) Citation

Robak, Tadeusz, et al. "Frontline Bortezomib, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (VR-CAP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Transplantation-ineligible Patients with Newly Diagnosed Mantle Cell Lymphoma: Final Overall Survival Results of a Randomised, Open-label, Phase 3 Study." Lancet Oncology, vol. 19, no. 11, 2018, p. 1449, https://doi.org/10.1016/S1470-2045(18)30685-5.